Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.115619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Shilpa S Dhar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. El…. Hauptthemen laut MEDLINE: Medulloblastoma, Histone Demethylases, Oxidative Phosphorylation, Enhancer Elements, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: ssdhar@mdanderson.org.
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
- Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
- Basic and Translational Research Division, Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: mglee@mdanderson.org.
Förderung
- NCI NIH HHS
- NICHD NIH HHS
- University of Texas MD Anderson Cancer Center
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
- Intellectual and Developmental Disabilities Research Center
- Baylor College of Medicine
- NIH
Zitieren
APA
Dhar, S. S., Brown, C., Rizvi, A., Reed, L., Kotla, S., Zod, C., Abraham, J., Abe, J. I., Rajaram, V., Chen, K., & Lee, M. G. (2025). Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115619
Vancouver
Dhar SS, Brown C, Rizvi A, Reed L, Kotla S, Zod C, et al. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115619
BibTeX
@article{Dhar2025,
author = {Dhar, Shilpa S and Brown, Calena and Rizvi, Ali and Reed, Lauren and Kotla, Sivareddy and Zod, Constantin and Abraham, Janak and Abe, Jun-Ichi and Rajaram, Veena and Chen, Kaifu and Lee, Min Gyu},
title = {Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.115619}
}
EUVIMED